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TCT-421
Bioresorbable Vascular Scaffolds in Coronary Interventions: 6-Month Results
From the German ASSURE-Registry
Detlef Mathey1
1Hamburg University Cardiovascular Center, Hamburg, Germany
Background: Bioresorbable vascular scaffolds have been available on the European
market since November 2011. The ﬁrst experience in a real-world setting is being
documented in the ASSURE registry (NCT01583608). The registry aims to investi-
gate the safety, efﬁcacy and performance of the everolimus-eluting, bioresorbable
vascular scaffold (BVS, ABSORB, Abbott Vascular Inc., Santa Clara, CA) over
a period of 3 years.
Methods: Consecutive patients with de novo native coronary artery disease were
treated with BVS at 6 German centers and included in the prospective, observational
registry. Acute and 6-months outcomes of equal weight were device success, proce-
dural success, cardiac death, myocardial infarction, ischemia driven target lesion
revascularization and target vessel failure or revascularization. Angiographic param-
eters were assessed at baseline and post procedure.
Results: A total of 183 patients (63.5  9.3 years, 79.8% male) were enrolled from
April 2012 to March 2013 and 198 lesions were treated. Eligibility criteria for
ABSORB A/B would have been met in 16% and for ABSORB EXTEND in 70% of
the patients. Acute device success was achieved in 194 (98%) lesions and acute
procedural success in all patients. No cardiac death or myocardial infarction occurred
and no target lesion revascularization was necessary during hospital stay. Median
lesion length was 14.5 mm (5-84 mm) with 85 (42.9%) lesions > 20 mm. 31 (15.7%)
lesions were moderately or heavily calciﬁed, 6 (3%) lesions were tightly angulated and
6 (3%) lesions involved a side branch  2 mm in diameter. Diameter stenosis was
77.9% at baseline and 4.8% post PCI on average. In 11 (5.6%) lesions diameter of
stenosis was  99%. The reference vessel diameter of 32 (16.2%) lesions was  2.5
mm. In 30 (15.2%) lesions > 1 BVS was implanted and in 11 patients > 1 target
vessel was treated. Bailout with a drug eluting stent was necessary in 3 (1.5%) lesions.
Conclusions: Acute results for safety, efﬁcacy and performance of BVS for de novo
coronary artery disease in all day clinical practice are promising. Angiographic core lab
results will be obtained by June 2013 and clinical 6-months results by September 2013.
TCT-422
Malapposition is observed more frequently and to a greater degree in
ﬁbrocalciﬁc plaques during bioresorbable vascular scaffold implantation
Liam M. McCormick1, Adam J. Brown1, Denise M. Braganza1, Stephen P. Hoole1,
Nick E. West1
1Papworth Hospital NHS Trust, Cambridge, United Kingdom
Background: The bioresorbable vascular scaffold (BVS) has several advantages over
existing metallic stents, including resorption and restoration of vasoreactivity.
However, the mechanical properties of the BVS do not allow aggressive post-dila-
tation, with potential for malapposition. Our aim was to assess the incidence of
malapposition and relation to plaque characteristics.
Methods: 22 patients undergoing BVS implantation were included (77.3% male; age
60.111.2yrs). Optical coherence tomography (OCT) was performed before/after
implantation. Two experienced OCT operators analyzed runs at 1mm longitudinal
intervals; where malapposition was seen, analysis was performed at 0.2mm intervals.
Malapposition was adjudicated and quantiﬁed, deﬁned as strut with 50% contact of
abluminal strut surface with endothelium. Tissue characterisation was deﬁned as the
predominant plaque composition in the quadrant of each strut. The degree of mal-
apposition was measured from adluminal strut edge to endothelium in a radial
direction, with strut width being 0.158mm.
Results: Target lesion was LAD 12, RCA 6, Cx 2 and SVG 2. Calciﬁcation was
absent (81.8%), mild (4.5%) and moderate (13.6%) on independent review. Median
number of BVS implanted was 1 (median size 3.0x18mm). Agreement on OCT-
deﬁned strut malapposition between observers was excellent (Kappa 0.847). In total,
766 frames of OCT were analysed (median 29.5 per case). 6798 struts were identiﬁed
with 436 (6.85%) being malapposed. Number of malapposed struts varied signiﬁ-
cantly (range 0-147, median 5, IQR 1-29). Fibrocalciﬁc plaque was more prevalent
when malapposition was present (46.6% vs. 8.3%, p<0.001). There was a positive
correlation between %calciﬁcation and malapposition (r¼0.44, p<0.001). The
distance of malapposition in ﬁbrocalciﬁc plaque was increased compared to other
malapposed struts (0.17mm0.10 vs. 0.14mm0.07, p¼0.01).
Conclusions: Incidence of strut malapposition with BVS is comparable to existing
DES platforms. However, malapposition is more frequent and occurs to a greaterJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrdegree in ﬁbrocalciﬁc plaques. Intracoronary imaging should be considered prior to
BVS, as unrecognized calciﬁcation may lead to unnecessary malapposition.
TCT-423
Bifurcation Strategies with the Absorb BVS Everolimus-Eluting Resorbable
Scaffold. A Bench Study
Jonathon White1, John A. Ormiston2, Ben Ubod3, Bruce Webber3, Mark W. Webster4
1Auckland Hospital, Auckland, New Zealand, 2Associate Professor, University of
Auckland Medical School, Auckland, New Zealand, 3Mercy Angiography, Auckland,
New Zealand, Auckland, New Zealand, 4AucklandCityHospital,Auckland,NewZealand
Background: While bifurcation stenting techniques with metallic stents have been
extensively studied on the bench and clinically, there are no data on how to treat
bifurcations with Absorb everolimus-eluting bioresorbable scaffolds (BRS) which have
limited post-dilatation potential without strut rupture compared with metallic scaffolds.
Methods: BRS were deployed in phantoms with 30, 60 and 90 side-branch angles in
water at 37C for testing strategies including side-branch dilatation with 2.5 and 3.0mm
balloons, main branch post-dilatation, kissing post-dilatation at 4 atmospheres pressure
and minimal balloon overlap, proximal optimization, "T" stenting with BRS and with
metallic stents, "T" with protrusion, Culotte technique, "Crush" technique, SKS technique.
The deployment steps were recorded using cine-angiography and ﬁnal results of each
technique were recorded photographically and withmicro-computed tomographic images.
Results: Dilating through the side of a BRS produced distortion similar to that with
metallic stents that was worse with smaller side-branch angles and bigger balloons.
The distortion consisted of narrowing of the scaffold beyond the side-branch and
malapposition of the struts opposite the side branch. The positive effect of distortion
occurred, with protrusion of struts into the side-branch. The distortion could be
partially repaired by main branch post-dilatation but was best repaired by low pressure
kissing post-dilatation. An unique feature of BRS use in bifurcations is the occurrence
of single scaffold hoop or connector rupture. These are of uncertain signiﬁcance.
Conclusions: Bench deployments of BRS provide insights into bifurcation strategies
with these unique devices that behave differently from metallic scaffolds.
TCT-424
Bifurcation Bench Testing With The Bioresorable Vascular Scaffold:
Implications For Clinical Use.
Pieter C. Smits1, Nic Debusschere2, Kees-Jan Royaards3, Matthieu De Beule4,
Peter Mortier4
1Maasstad Hospital Rotterdam, Rotterdam, Netherlands, 2Ghent University, Ghent,
Belgium, 3Maasstad Hospital, Rotterdam, Netherlands, 4FEops / Ghent University,
Gent, Belgium
Background: Little is known about bifurcation treatment with the bioresorable
vascular scaffold (BVS) from Abbott. In a bench test we investigated the mechanical
properties and integrity of BVS in different bifurcation models
Methods: In a warm water bath of 36 degrees Celsius multiple BVS were tested in 2
models. Model A. Opening towards an artiﬁcial side branch (SB) of a 3.0 mm BVS
was investigated with increasing balloon sizes through a mid BVS cell under an angle
of 30 and 60 degrees. Model B. With a 3D printer, 6 bifurcation models consisting of
a rubber-like material (TangoPlus) with moderate stenosis (Medina 1-1-0) and 60
degree SB angle were made with the proper sizing of the proximal main branch
(PMB), SB and distal main branch (DMB) using a validated scaling law. In these
models 2.5, 3.0 and 3.5 mm BVS were implanted in the MB. Sequentially, SB
opening was done using single 2.0 or 2.5 mm balloons (4 models) or using 2.0 and 3.0
mm balloons for complete (1 model) and incomplete kissing/snuggle (1 model).
Opening and distortion of the BVS struts were investigated with OCT and microCT.
Results: In model A, without surrounding structures, a cell of a 3.0 mm BVS can be
expanded with 1.5 and 2.5 mm balloons at high pressure (16 atm) without disrupting
struts. With a 3.0 balloon at 30 degree angle at 10 atm. and with 3.5 balloon at 60
degree angle at 8 atm. 1 or more struts ruptured. In model B, all 3D models showed no
strut ruptures by OCT. By microCT only one partial strut tear was seen after
incomplete kissing balloon. By OCT and microCT identical scaffold distortions of the
PMB and DMB were observed, similar to what has been described with metallic
stents. Distal struts adjacent to the SB were deﬂected into the lumen and proximal
struts adjacent to the SB were deﬂected towards the SB opening. Furthermore, struts
opposite the SB were deﬂected inwards causing malapposition. Increasing SB balloon
size showed increased malapposition up to 270 um. With double balloon inﬂation
technique no malapposition was noted.
Conclusions: These results support the concept that bifurcation treatment with BVS is
feasible and that similar strategies for provisional sidebranch treatment apply as to
metallic stent.
TCT-425
Real-World Experience with Absorb Bioresorbable Scaffold Technology -
Early Australian Registry Results
Nigel Jepson1, Clare Arnott1, Liam Back1, Sze-yuan Ooi1, Mark Pitney2
1Prince of Wales Hospital, Sydney, NSW, 2Sutherland Hospital, Sydney, NSW
Background: The safety and efﬁcacy of the Absorb bioresorbable scaffold (ABS)
has been documented in lower-risk lesion subsets however outcome data in moreacts/POSTER/Bioresorbable Vascular Scaffolds B131
